European Neuropsychopharmacology (v.13, #S4)

P.3.007 Photosensitivity and affective disorders: Relationship with anxiety symptomatology by M. Martinucci; L. Bossini; A. De Capua; K. Paolini; P. Castrogiovanni (S356-S357).

P.3.011 Reduced brain serotonin transporter binding in patients with panic disorder by E. Maron; J.T. Kuikka; J. Shlik; V. Vasar; E. Vanninen; J. Tiihonen (S358-S359).

P.3.006 Effects of cannabidiol (CBD) on regional cerebral blood flow by A. Zuardi; J.A. Crippa; G.E. Garrido; L. Wichter-Ana; R. Guarnieri; L. Ferrari; P.M. Marques; J.E.C. Hallak; P.K. Mc Guire; G.F. Busato (S356).

P.3.002 Megestrol attenuates hormonal response to CCK-4 by T. Raedler; H. Jahn; B. Goedecken; D.M. Gescher; M. Kellner; K. Widemann (S354).

P.3.003 Sensitivity to carbon dioxide in subjects with a single lifetime panic attack by E. Berzak; M. Reznik; O. Narsia; J. Benjamin (S354).

P.3.012 Effect of the cortisol synthesis inhibitor, metyrapone, on anxiety before and after carbon dioxide challenge in panic disorder by L. Knyazhansky; U. Loewenthal; J. Arbelle; H. Cohen; A. Belgorodsky; J. Benjamin (S359).

P.3.018 Decreased TNF-α, IL-6, and NK activity in obsessive-compulsive disorder by D. Denys; S. Fluitman; A. Kavelaars; C. Heijnen; H.G.M. Westenberg (S361).

P.3.014 Stress increases susceptibility to oxidative damage in an experimental model of colitis in rats by J.C. Leza; A. Colón; J.L.M. Madrigal; L. Menchén; O. Hurtado; M.A. Moro; I. Lizasoain; J.C. Leza; P. Lorenzo (S359-S360).

P.2.169 Amygdala volume abnormalities in chronic schizophrenia by K. Kucharska-Pietura; P. Shaw; T. Russell; M.L. Phillips; A.S. David (S353).

P.2.167 Predictive factors associated to clinical outcome in schizophrenic patients treated with clozapine by M.C. Mauri; L.S. Volonteri; A. Fiorentini; G. Cerveri; S. Beraldo; M.L. Baldi; G. Panza; S. Bareggi (S353).

P.2.151 Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's dementia by P.P. De Deyn; M.M. Carrasco; W. Deberdt; C. Jeandel; D.P. Hay; P.D. Feldman; C.A. Young; D.L. Lehman; A. Breier (S345).

P.2.152 Ziprasidone in mania: A 21-day randomized, double-blind, placebo controlled trial by S. Segal; R.A. Riesenberg; K. Ice; P. English (S345-S346).

P.2.148 Dissociation of amygdala and visual cortex sensitivity for unpleasant facial expression in first-episode schizophrenic patients: An fMRI study by R. Strous; M. Bleich; R. Even; H. Harari; P. Pianka; P. Rotshtein; M. Kotler; T. Hendler (S343-S344).

P.2.144 Oxidative stress in patients suffering from schizophrenia by N. Petronijevic; D. Marinkovic; D.V. Micic; B. Djuricic; V.R. Paunovic (S342).

P.2.145 The effectiveness of olanzapine versus plasma in maintaining the quality of life in stabilized patients with schizophrenia by C.M. Beasley; D.J. Walker; V.K. Sutton; K. Alaka; D. Naber; M. Namjoshi (S342-S343).

P.2.163 Sexual side effects of novel antipsychotics by S. Kesebir; B. Veznedaroglu; S. Pyryldar; B. Kayahan (S351).

P.2.162 Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: Interim results of a randomised, rater-blinded study by E. Sacchetti; P. Valsecchi; C. Regini; A. Galluzzo; P. Cacciani; E. Agrimi; C. Mencacci (S350-S351).

P.2.158 Donepezil as an adjunctive treatment of cognitive dysfunction in schizophrenia by M. Tuma; Z. Lenderova; M. Zemanova; E. Kadlecova; M. Pérez (S348-S349).

P.2.159 Long term treatment of chronic schizophrenia with risperidone by A. Karastergiou; A. Kanistras; G. Papadam; D. Kontis; A. Fotopoulos (S349).

P.2.160 Combination treatment with risperidone and diazepam in drug-naive schizophrenic patients by V.P. Kontaxakis; B.J. Havaki-Kontaxaki; S.S. Stamouli; G.N. Christodoulou (S349).

P.3.024 Efficacy of sertraline in posttraumatic stress disorder secondary to interpersonal trauma or childhood abuse by D.J. Stein; B. Van der Kolk; C. Austin; R. Fayyad; C. Clary (S363-S364).

P.3.058 Venlafaxine XR and paroxetine in the short-term treatment of panic disorder by U. Lepola; M. Pollack; G. Emilien; E. Tzanis; T. Whitaker (S378).

P.3.057 Treatment of panick disorder with venlafaxine XR by A. Ahokas; J. Bradwejn; G. Emilien; T. Whitaker (S377-S378).

P.3.051 Efficacy of sertraline for the acute treatment of generalized anxiety disorder (GAD) by P.L.P. Morris; A.A. Dahl; S.P. Kutcher; J.A. Sogaard; C. Allgulander; T. Burt (S375).

P.3.053 Primary anxiety disorders: Impact of treatment on subsequent depression and health outcomes by L. Russo; J. Alonso; H. Bryson; R. Kessler; J.P. Lépine; J.M. Haro; V. Kovess; K. Demyttenaere; I. Gasquet; G. De Girolamo; S. Katz; M. Angermeyer; R. De Graaf; H. Ormel; G. Polidori; T. Brugha; P. Richetta (S376).

P.3.062 Venlafaxine XR and sertraline in PTSD: A placebo-controlled study by J.R.T. Davidson; A. Lipschitz; J. Musgnung (S380).

P.3.063 Long-term treatment of generalized social anxiety disorder with venlafaxine XR by D. Hackett; M.B. Stein; R. Mangano; M. Pollack (S380-S381).

P.3.070 CCK2 receptor deficient mice: Changes in anxiety and pain sensitivity by E. Vasar; S. Koks; U. Abramov; J. Innos; S. Raud; K. Kurrikoff; V. Volke; M. Bourin; T. Matsui (S384).

P.3.072 SB-616234-A — a novel, potent and selective 5-HT1B receptor antagonist by J. Watson; C. Scott; C.J. Langmead; P. Wyman; P.W. Smith; L.A. Dawson; G.W. Price (S385).

P.3.069 Placebo response and anxiety disorders: A critical evaluation of influential variables by C.S. Wilcox; B.B. Katz; J.F. Heiser; F.E. Cho; J.L. Morrissey; D.E. Grosz; A.I. Hardy; D.F. DeFrancisco (S383-S384).

P.3.068 Regional gray matter density and correlates of disease severity in panic disorder by G. Massana; P. Salgado-Pineda; J.M. Serra-Grabulosa; C. Gastó; C. Junqué; J. Massana; J.M. Mercader (S383).

P.3.067 Decreased lymphocyte 3H-paroxetine binding in obsessive-compulsive disorder by I. Masala; S. Baroni; L. Betti; G. Giannaccini; F. Mungai; D. Marazziti (S382-S383).

P.3.049 Decreased temporal lobe volume in panic disorder - a quantitative morphometric MRI study by T. Sobanski; G. Wagner; U. Gruhn; K. Schluttig; R. Tauber; G. Peikert; H. Sauer (S374).

P.3.033 Failure to find DUP25 in patients with anxiety disorders, in control individuals, or in previously reported positive control cell lines by M. Tabiner; S. Youings; N. Dennis; D. Baldwin; C. Buis; A.G. Mayers; P.A. Jacobs; J.A. Crolla (S367).

P.3.034 Joint hypermobility syndrome in panic disorder patients with and without mitral valve prolapse by D. Gulpek; E. Bayraktar; S. Pyryldar; K. Capacy; M. Kayykcyoglu; E. Aliyev; C. Soydas (S367-S368).

P.3.045 Role of gonadal steroids in the anxiolytic action of benzodiacepines in male and female mice lacking cannabinoid CB1 receptors by L. Urigüen; M. Grau; S. Pérez-Rial; S. Ortiz; J.M. Oliva; T. Palomo; J. Manzanares (S372).

P.3.046 Altered emotional states and impaired anxiolytic action of benzodiacepines in mice lacking cannabinoid CB1 receptors by L. Urigüen; S. Pérez-Rial; S. Ortiz; J.M. Oliva; T. Palomo; J. Manzanares (S373).

P.3.047 Autoantibody binding profile to the brain and pituitary in neuropsychiatric disorders by S. Fetissov; J. Hallman; L. Oreland; T. Hökfelt (S373).

P.3.044 Social anxiety disorder and female reproductive hormones: Is there a connection? by J.F. Van Veen; B.W. Jonker; I.M. Van Vliet; F.G. Zitman (S372).

P.3.043 Dopamine transporter density changes of basal ganglia with SSRI treatment i patients by M.-S. Koo; C.H. Kim; K.-A. Cheon; H.S. Suh; H.S. Lee; Y.-H. Ryu (S371).

P.3.040 Relapse in social anxiety disorder (SAD): Costs and quality of life by D. Servant; S.A. Montgomery; C. François (S370).

P.3.042 TNF-alpha accounts for stress-induced short-term persistency of oxidative status in rat brain by C. Munhoz; J.L.M. Madrigal; B. García-Bueno; M.P. Pereira; M.A. Moro; I. Lizasoain; P. Lorenzo; J.C. Leza (S371).

P.2.074 Psychotropic polypharmacy among medicaid subjects by M. Rupnow; J.S. Markowitz; A. Grogg (S311-S312).

P.2.077 Neurological soft signs in first-episode schizophrenia by E. Ceskova; R. Prikryl; T. Kasparek; E. Tronerova (S313).

P.2.072 A French cohort study on olanzapine prescription over a 12 months period by V. Olivier; A. Fourrier; I. Gasquet; P. Flandre; E. Perrin (S310-S311).

P.2.068 Antipsychotic treatment for schizophrenia: Effects on sexual function by C. Osvaldo; M. Dossenbach; J.M. Tamayo; D. Soria; C. Na; S. Singh; K.-H. Wu (S308-S309).

P.2.069 Quality of life and clinical outcomes for Asian outpatients with schizophrenia: A double-blind randomised comparison of olanzapine and haloperidol by H.R. Chaudhry; R. Kongsakon; J.C. Ignacio; S.B. Raza; M.C.R. Leynes; C.I. Hasanah; B. Chan; P. Onate; A.J.M. Brnabic; A.J. Lowry; R. Buenaventura (S309).

P.2.087 Risperidone monotherapy in acute bipolar mania by M. Kramer; K. Karcher; F. Grossman (S317-S318).

P.2.088 Dopaminergic system genes and performance on prefrontal test in schizophrenia by J. Rybakowski; A. Borkowska; P.M. Czerski; J. Hauser (S318).

P.2.089 Switching from clozapine to zotepine in schizophrenic patients: A randomized, single-blind controlled study by C.-C. Lin; Y.-M. Bai; J.-Y. Chen; Y.-C. Wang; Y.-J. Liou; C.-H. Chao; I.-C. Lai; K.-Y. Tsai; H.-J. Chiu (S318-S319).

P.2.090 Metabolite abnormalities in glutamatergic system measured by proton magnetic resonance spectroscopy (1H MRS) in schizophrenic patients by B. Galinska; A. Szulc; E. Tarasow; B. Kubas; W. Dzienis; A. Czernikiewicz; J. Walecki (S319).

P.2.086 Atypical antipsychotics and time of hospitalization by M. García Mahía; M. Vidal Millares; R. Garcia Ramos; C. Pedrejon Molino; C. Borras (S317).

P.2.085 Amphetamine and stress-induced behaviors and c-Fos expression in a genetic model of NMDA receptor hypofunction by S. Miyamoto; J.N. Snouwaert; B.H. Koller; J.A. Lieberman; G.E. Duncan (S317).

P.2.081 A preliminary study of the pharmacokinetics and tolerability of higher dose oral olanzapine (20, 30, or 40mg/day) in stable patients with serious mental disorders by M. Mitchell; W. Earley; M.A. Bari; R.A. Riesenberg; E. Marquez; D. Kurtz; D. Falk; C.C. Taylor; P. Cavazzoni (S315).

P.2.082 Cognitive function in patients with Alzheimer's dementia during double-blind treatment of psychosis with olanzapine by W. Deberdt; P.P. De Deyn; M.M. Carrasco; C. Jeandel; D.P. Hay; P.D. Feldman; C.A. Young; D.L. Lehman; A. Breier (S315).

P.2.083 Pilot study of the effects of rivastigmine in schizophrenia by K.M. Van de Graaff; A.J.M. Loonen; J.E.J.M. Hovens; A. Van Dijke; J.H.M. Tulen (S315-S316).

P.2.067 An analysis of tardive dyskinesia in intercontinental outpatients with schizophrenia by S. Kasper; A.J. Lowry; A. Hodge; I. Bitter; M. Dossenbach (S308).

P.2.066 Effectiveness of antipsychotic treatments for patients from the Central Eastern Europe (CEE) region participating in the 3-year intercontinental schizophrenia outpatient health outcomes (IC-SOHO) observational study: 6-month results by J. Pečeňák; P. Kaps; T. Treuer; I. Bitter; A. Hodge; A. Grigoriu; I. Trzebiatowska; E. Herman; D. Peciukaitiene; S. Smulevich; M. Kökényes (S307-S308).

P.2.051 Ziprasidone negative symptom efficacy in long-term clinical trials by N.R. Schooler; S. Murray; C.O. Siu; S.J. Romano (S301).

P.2.047 Analysis of motor function in patients with Alzheimer's dementia during double-blind treatment of psychosis with olanzapine by W. Deberdt; M.M. Carrasco; C. Jeandel; D.P. Hay; P.D. Feldman; C.A. Young; D.L. Lehman; A. Breier; P.P. De Deyn (S299).

P.2.044 The specificity of autobiographical memory and emotional disturbance in schizophrenia by D. Lecompte; A. Neumann; S. Blairy; P. Philippot; J.M. Danion (S298).

P.2.045 A family overloaded with psychosis and rickets-alopecia syndrome challenges vitamin-D hypothesis for schizophrenia by S. Ozer; A. Ulusahin; S. Ulusoy; H. Okur; T. Coskun; A. Gogus; A.N. Akarsu (S298-S299).

P.2.046 Ziprasidone versus risperidone in schizophrenia: 52 weeks' comparative data by D. Addington; C. Pantelis; M. Dineen; I. Benattia; S.J. Romano; S. Murray (S299).

P.2.054 Adherence to antipsychotic dosing guidelines in the treatment of hospitalised psychotic patients in Belgium by J. Peuskens; M. Wampers; I. Fernandez; E. Thys; S. Wyckaert; M. De Hert (S302).

P.2.063 Antipsychotic medication treatment and new prescriptions for insulin and oral hypoglycemics by L. Citrome; A. Jaffe; J. Levine; B. Allingham; J. Robinson (S306).

P.2.060 Antidepressant-type effects of olanzapine in modified FST in rats by B.L. Cobo-Realpe; M.O. Rojas-Corrales; E. Berrocoso; J. Gibert-Rahola; J.A. Micó (S305).

P.2.056 Sound and vision, using popular media to improve knowledge about schizophrenia by E. Thys; M. De Hert; G. Magiels; S. Wyckaert; J. Peuskens (S303).

P.2.058 Pharmacodynamic differences between ziprasidone, risperidone and haloperidol: A 123I-IBZM study by M. Ferrer Vinardell; I. Corripio Collado; G. Safont Lacal; R. Pérez Egea; V. Pérez Solá; E. Alvarez Martínez (S304).

P.2.092 Quality of life and cognitive functions in schizophrenia by Y. Akvardai; B.B. Kivircik; K. Alptekin; K. Dumlu; D. Isik; F. Pirincci; S. Yahssin; A. Kitis (S320).

P.2.127 Aripiprazole in pediatric-conduct disorder: A pilot study by R.L. Findling; J.L. Blumer; R. Kauffman; J.R. Batterson; D.L. Gilbert; S. Bramer; R. Marcus (S335).

P.2.128 Metabolic effects associated with antipsychotic therapy in a naturalistic setting by D. Schreinzer; M. Letmaier; C. Barnas; S. Kasper (S335-S336).

P.2.123 Atypical antipsychotic treatment-related urinary incontinence: A urodynamic evaluation by G. Martino; S. Isgrò; G. Martino; E. Di Rosa; R. Zoccali; G. Citto; M. Meduri (S333-S334).

P.2.118 SPECT quantification of in vivo dopamine D2 receptor occupancy with risperidone microspheres by G. Wiesegger; N. Klein; S. Asenbaum; T. Attarbaschi; N. Mossaheb; R. Dudczak; S. Kasper; J. Tauscher (S331-S332).

P.2.120 Time of dosing and food effect on aripiprazole pharmacokinetics by S. Mallikaarjun; Y. Riesgo; D. Salazar; S. Bramer; J. Xie; I. Weston (S332-S333).

P.2.121 Aripiprazole vs. haloperidol for maintained treatment effect in acute mania by M. Bourin; P. Auby; S. Swanik; R. Marcus; R. McQuade; T. Iwamoto; R. Sanchez (S333).

P.2.140 A comparison of the efficacy and safety of quetiapine and risperidone by X. Zhong; D. Sweitzer; J. Russo; L. Potter; J. Mullen (S340).

P.2.136 Premorbid functioning and outcomes in recent onset schizophrenia by J. Rabinowitz; G. De Smedt; M. Davidson (S338-S339).

P.2.131 Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia by R.S. Kahn; J.A. Lieberman; C. Charles; T. Sharma; R.B. Zipursky; R. Gur; M. Tohen; A.I. Green; J.P. McEvoy; D.O. Perkins; R.M. Hamer; C.B. Nemeroff; A.J. Rothschild; J. Kuldau; S.M. Strakowski; G.D. Tollefson (S337).

P.2.117 Development of a genetic test for the prediction of clozapine response by H.M. Puehringer; M.J. Arranz; R.W. Kerwin; F. Kury; C. Oberkanins (S331).

P.2.116 Guanosine-5′-O-(3-[35S]THIO)-triphosphate binding assays can be insensitive in detecting D2 partial agonist drug activity by S. Jordan; R. Chen; J. Johnson; K. Regardie; R. Whitehead; Y. Tadori; R. McQuade; T. Kikuchi (S331).

P.2.100 Sertindole is superior to haloperidol in cognitive performance in patients with schizophrenia: A comparative study by S. Lis; S. Krieger; B. Gallhofer; P. Torre; A. Mittoux; F. Menard (S323-S324).

P.2.102 Aripiprazole treatment for psychosis in patients with Alzheimer's disease by P.P. De Deyn; D. Jeste; P. Aubrey; H. Goyvaerts; C. Breder; L. Schneider; J. Mintzer (S325).

P.2.098 Risperidone augmentation on resistant depression by A. Young; F. Rouillon; C. Canuso; C. Bossie; G. Gharabawi (S323).

P.2.097 The immune system abnormalities in first-episode schizophrenia by A. Szulc; B. Galinska; B. Konarzewska; R. Poplawska; A. Czernikiewicz (S322-S323).

P.2.093 Marked increase in adiposity during olanzapine vs risperidone treatment: Results of a placebo-controlled study in normal dogs by M. Ader; S.P. Kim; K.J. Catalano; V. Ionut; K. Hucking; J.M. Richey; M. Kabir; R.N. Bergman (S320-S321).

P.2.096 No association between serotonin transporter polymorphism and schizophrenia by P. Kapelski; P. Czerski; J. Hauser; A. Leszczynska-Rodziewicz; M. Skibinska; M. Dmitrzak-Weglarz; J. Rybakowski (S322).

P.2.105 Efficacy and safety of aripiprazole versus perphenazine in treatment-resistant schizophrenia by R. McQuade; D. Jody; J. Kane; W. Carson; M. Kujawa; J. Stringfellow; R. Marcus; R. Sanchez; H.Y. Meltzer (S326).

P.2.113 An open-label trial of topiramate adjunct in bipolar patients with mood instability by C. Binder; R. McIntyre; R. Riccardelli; V. Kusumakar (S329).

P.2.114 Cross-domain analyses in schizophrenia — results from human brain informatics studies by H. Hall; S. Arnborg; I. Agartz; A. Sillén; E.G. Jonsson; B. Edman; H. Nyman; L. Terenius; G. Sedvall (S330).

P.2.115 PET examinations or thalamic D2 receptors in schizophrenic patients by M. Talvik; A.L. Nordström; H. Olsson; C. Halldin; L. Farde (S330).

P.2.111 Long-term effects of aripirazole on the negative symptoms of schizophrenia by D. Kostic; G. Manos; E. Stock; D. Jody; D. Archibald; S. Tourkodimitris; R. Marcus (S328).

P.2.110 A case of schizophrenia-like psychosis in a patient with temporal arachnoid cyst by M. Fontana; T. Di Fonzo; C. Aliquò; A. Hadjichristos (S328).

P.2.106 Change in clinical status and quality of life of schizophrenic patients in Germany: Six month results from the schizophrenia outpatient health outcomes (SOHO) study by D. Naber; M. Krausz; R.W. Dittmann; C. Mahl; F. Langer; T. Wagner; P. Linder; D. Novick; J. Czekalla (S326-S327).

P.2.108 Plasma lipids levels and glycemic control in long-term treatment with aripiprazole by E. Stock; S.R. Marder; D. Jody; S. Kaplita; A. Saha; W. Carson; A. Torbeyns (S327).

P.2.109 A double-blind placebo-controlled trial of risperidone in autistic disorder by C.J. McDougle; M.G. Aman; J.T. McCracken; L. Scahill; E. Tierney; B. Vitiello (S327-S328).

P.3.075 Duration of untreated illness in panic disorder: A poor outcome risk factor? by E. Mundo; A. Santini; D. Salvadori; A.C. Altamura (S386).

P.6.029 Fractal analysis of magnetic resonance images in schizophrenia and obsessive-compulsive disorder by J.S. Kwon; U. Yoon; J.M. Lee; T.H. Ha; L.Y. Kim; S.I. Kim (S438).

P.6.028 Mirtazapine orally disintegrating tablets in depressed patients who are at least 50 years of age by S.P. Roose; P. Holland; H. Hassman; M. Rosenthal; J.H. Simmons; H. Rodrigues (S437).

P.6.030 Brain-derived neurotrophic factor polymorphism in patients with schizophrenia by A. Juhasz; A. Rimanoczy; S.Z. Keri; G.Y. Szekeres; Z. Janka (S438).

P.6.031 An association of the serotonin receptor (5HT2A) gene and serotonin transporter (5HTTLPR) gene in anorexia nervosa by M. Dmitrzak-Weglarz; F. Rybakowski; A. Slopien; P. Czerski; J. Hauser; A. Rajewski (S438-S439).

P.6.032 Complex partial scizure-like symptoms, dissociation and traumatic stress in depressed patients by P. Bob; R. Ptacek; I. Paclt; P. Zvolsky; D. Jasova; J. Pavlat; M. Pav (S439).

P.6.027 Effects of secluded areas in a psychiatric acute ward by A.E. Vaaler; G. Morken; J.C. Flovig; V.C. Iversen; O.M. Linaker (S437).

P.6.026 Caffeine influenced time-perception in humans by I. Ghita Cristescu; O. Comar; O. Savo; C. Rotar; I. Fulga (S436-S437).

P.6.023 Association study of dopamine system genes in anorexia nervosa by A. Slopien; F. Rybakowski; M. Dmitrzak-Weglarz; J. Hauser; A. Rajewski (S435-S436).

P.6.025 Neuropsychological correlations of obsessive-compulsive disorder symptom dimensions by T.H. Ha; J.S. Kwon; K.S. Roh; H.S. Park; M.S. Kim (S436).

P.6.033 Decline in CYP2D6 metabolising capacity in the elderly by K. Tandon; M. Kinirons; M. Patel; P. McGuffin; K.J. Aitchison (S439-S440).

P.6.034 Endocrine responses to ghrelin in patients with eating disorders by G. Abbate Daga; V. Mondelli; P. Leombruni; S. Destefanis; F. Broglio; F. Facchini; S. Defilippi; R. Rosetto; F. Lanfranco; R. Deghenghi; E. Ghigo; L. Gianotti; S. Fassino (S440).

P.6.041 Mental disorders in patients with Lyme disease by I. Rudnik; R. Poplawska; A. Szulc; D. Juchnowicz; B. Konarzewska; A. Czernikiewicz; I. Debowska (S443).

P.6.042 Species differences in the antinociceptive activity of 3-carbomethoxy fentanyl (iso-carfentanil) by M. Prostran; S. Vuckovic; M. Ivanovic; Z. Todorovic; Z. Nesic; R. Stojanovic (S444).

P.6.043 No association between DRD4 gene -521 C/T polymorphism with schizophrenia and bipolar affective disorder by P. Czerski; M. Dmitrzak-Weglarz; P. Kapelski; A. Leszczynska-Rodziewicz; M. Kosmowska; M. Perucki; J. Hauser (S444).

P.6.044 Repetition of suicidal behaviour following deliberate self-poisoning with pesticides by K. Naudts; G. Portzky; K. Audenaert; C. Van Heeringen (S444-S445).

P.6.040 Is the Brugada electrocardiogram associated with antipsychotic and antidepressant treatment? by S. Kounas; O. Rouvali; P. Dalli; M. Efremidis; S. Theodoropoulou; F. Kardaras (S443).

P.6.035 Diffusion-weighted MRI study of corpus callosum in patients with schizophrenia. Preliminary findings by P. Brambilla; R. Cerini; C. Barbui; A. Gasparini; M. Nose; A. Versace; E. Vittom; N. Andreone; M. Gregis; A. David; M.S. Keshavan; C. Procacci; M. Tansella (S440-S441).

P.6.036 Comparison of divalproex and gabapentin: Effectiveness in aggressive youth by S. Komdorfer; W. Beardslee; J. Gonzalez-Heydrich (S441).

P.6.037 Effect of 5-HT2C receptor activation on reward and loss response patterns in humans detected by fMRI by J. Stirling; B. Völlm; P. Richardson; C. Del Ben; R. Elliott; I. Anderson; S. McKie; B. Deakin; W. Williams (S441-S442).

P.6.038 Acute exposure to higher ambient temperature potentiates cataleptic and hyperthermic effects of fentanyl in female rats by M. Prostran; Z. Nesic; S. Vuckovic; M. Prostran; Z. Todorovic; R. Stojanovic; M. Ivanovic (S442).

P.6.021 Anxiety, depression and disease specific quality of life in dermatologic patients by A. Yazici; K. Baz; K. Yazici; A. Köktürk; Y. Okyay; A. Cordan Yazici; D. Demirseren (S435).

P.6.020 Association of the TAP2 gene with schizophrenia in the Korean population by T.Y. Jun; K.-U. Lee; J.M. Song; C.U. Pae; J.H. Chae; W.M. Bahk; K.S. Kim (S434-S435).

P.6.004 Study of substance use impact on the severity of parasuicide by M. Tournier; M. Molimard; A. Abouelfath; A. Cougnard; A. Fourier; H. Verdoux (S428).

P.6.002 Behavioral phenotyping of GSK-3 beta knockout heterozygote mice by Y. Bersudsky; A. Shaldubina; G. Agam; N. Kozlovsky; K. Hoeflich; J.R. Woodgett; R.H. Belmaker (S428).

P.6.001 Relationships between DRD2 and DAT polymorphisms and personality traits in healthy subjects by E. Pinto; J. Reggers; M. Hansenne; W. Pitchot; S. Fuchs; P. Gorwood; D. Vaira; M. Ansseau (S427-S428).

P.5.048 Effects of fluoxetine on ethanol withdrawal syndrome in rats by H. Kayir; E. Saglam; T. Çelik; M. Beyazyurek; I.T. Uzbay (S426-S427).

P.6.016 Type A behavior and estrogen levels in women under 50 years old with acute coronary syndrome by J. Dragicevic; Z. Vasiljevic; M. Drezgic; V. Bisenic; P. Mitrovic; M. Krotin (S433).

P.6.017 Systematic screen of serotonergic genes on suicidal behaviour by I. Giegling; D. Rujescu; R.R. Engel; H.-J. Möller (S433).

P.6.014 The frequency and associated factors of excessive daytime sleepiness in Korean young men by S.P. Lee; S.C. Hong; J.H. Han; J.H. Jeong; S.H. Lim (S432-S433).

P.6.01 Evaluation of risperidone mutagenic action by sister chromatide exchange test by A. Damjanovic; M. Ivkovic; M. Jasovic-Gasic; V.R. Pauncvic (S431).

P.6.011 Subtypes of autism by cluster analysis based on structural MRI data by M. Hrdlicka; I. Dudova; I. Beranova; J. Lisy; T. Belsan; J. Neuwirth; V. Komarek; L. Faladova; Z. Sedlacek; M. Havlovicová; M. Blatny; T. Urbanek (S431-S432).

P.6.012 Carbamazepine for the treatment of behavioral disturbances of dementia by R. Krsteska; V. Filovska; M. Jakovcevska-Kujundziska (S432).

P.6.045 SSRI fail to improve AN treatment in first weeks of treatment by M. Janas-Kozik; I. Krupka-Matuszczyk; M. Krzystanek; J. Szymszal (S445).

P.6.046 Phosphorylation of ERK and CREB in cultured hippocampal neurons after haloperidol and risperidone administration by S.H. Kim; B.H. Yang; H. Son; J.H. Nam; J.H. Choi; J.S. Lee; H.S. Oh; K.S. Rho; D.H. Oh (S445).

P.6.080 Long-term exposure to lithium therapy and side effects with common dosing by V. Filovska; M. Jakovcevska-Kujundziska; M. Lazarova; R. Krsteska (S459-S460).

P.6.079 [3H]-Ketanserin binding sites in different psychiatric disorders by D. Marazziti; G. Giannaccini; A. Giromella; L. Betti; S. Baroni; I. Masala; A. Lucacchini; G.B. Cassano (S459).

P.6.081 Topiramate in bipolar and schizoaffective disorders by A. Theodorou; C. Kalkavoura; P. Theodoropoulou; A. Georgiou; E. Tzebelikos (S460).

P.6.083 Management of attention-deficit/hyperactivity disorder (ADHD) in The Netherlands by N. Vanoverbeke; L. Annemans; M. Ingham; I. Adriaenssen (S461).

P.6.078 DRD4 gene polymorphism in Turkish children and adolescents with developmental stuttering by A. Ertekin Yazici; F. Toros; E. Erdal; S. Zoroglu; S. Tot; A. Yazici Ertekin (S459).

P.6.077 Long-term effects of atomoxetine on growth in children with APHD by D. Michelson; T. Spencer; D. Ruff; P.D. Feldman (S458-S459).

P.6.073 Treatment and economic outcomes in patients with bipolar disorder by K. Davis; N. Calvert; A. Lloyd; M. O'Leary; P. Youman (S457).

P.6.092 Both methylphenidate and acetyl-L-carnitine reduce impulsivity in adolescent SHRs, an animal model of ADHD by W. Adriani; M. Baviera; W. Invernizzi; M. Carli; A. Caprioli; O. Ghirardi; G. Laviola (S465).

Author index (S467-S482).

Keyword index (S483-S488).

P.6.090 Alexithimia anxiety and depression in patients with bronchial asthma by A. Karkanias; G. Moussas; D. Stamouli; A. Tselebis; Th. Bakogianni (S464).

P.6.087 Executive functions in remitted schizophrenic patients: A preliminary study by G. Saba; C.M. Verdon; V. Moulier; G. Dumortier; K. Kalalou; J.F. Rocamora; R. Benadhira; L. Stamatiadis; D. Januel (S462-S463).

P.6.089 Chromosome 3q29: Follow-up linkage analysis in schizophrenia and bipolar disorder by A. Schosser; K. Fuchs; F. Leisch; U. Bailer; S. Kasper; W. Sieghart; K. Hornik; H.N. Aschauer (S463-S464).

P.6.072 Placebo-controlled study of once-daily atomoxetine in the school setting by M. Weiss; R. Tannock; C. Kratochvil; D. Dunn; J. Velez-Borras; C. Thomason; L. Lambrecht; R. Tamura; D. Kelsey; A.J. Allen (S456-S457).

P.6.071 Structural brain abnormalities in obsessive-compulsive disorder (OCD) by T. Sobanski; G. Wagner; U. Gruhn; A. Herwig; R. Tauber; G. Peikert; H. Sauer (S456).

P.6.055 Nettrocognitive functioning and theory of mind in schizophrenia by R. Herold; T. Tényi; M. Simon; M. Trixler (S449).

P.6.056 Minor physical anomalies in Tourette syndrome by T. Tényi; J. Gádoros; G. Csábi; S. Jeges; E. Gyenge; M. Trixler (S449-S450).

P.6.047 No association between DRD2 and DRD3 gene polymorphism and bipolar affective disorder by M. Kosmowska; M. Skibinska; M. Kaczmarkiewicz-Fass; A. Leszczynska-Rodziewicz; P. Kapelski; P. Czerski; J. Rybakowski; J. Hauser (S446).

P.6.048 BDNF Val66Met polymorphism in bipolar affective disorder and schizophrenia — association with early age of onset in schizophrenia by M. Skibinska; P. Czerski; A. Leszczynska-Rodziewicz; M. Kosmowska; P. Kapelski; J. Hauser; J. Rybakowski (S446).

P.6.050 Tramadol in the treatment of persistent pain in the elderly by M. Prostran; L.B. Jovanovic; L.J. Zikic; S. Vuckovic (S447).

P.6.059 Leptin and glucose metabolism in eating disorders by A. Gáti; F. Tury; I. Wittmann (S450-S451).

P.6.060 Influence of psychopharmacologic treatment on short-term actigraphic measurements by D. Winkler; E. Pjrek; L. Pezawas; A. Konstantinidis; O. Presslich; J. Tauscher; S. Kasper (S451).

P.6.068 Once-daily atomoxetine in childhood ADHD: Continuous symptom relief by A.J. Allen; D. Kelsey; C. Sumner; V.K. Sutton; J. Gonzales; S. Malcolm; K. Schuh; D. Michelson (S454-S455).

P.6.070 Atomoxetine in the long-term prevention of relapse in ADHD by D. Michelson; J. Buitelaar; M. Danckaerts; C. Gillberg; T.J. Spencer; A. Zuddas; S. Zhang; J. Biederman (S455-S456).

P.6.065 MDMA-evoked changes in [11C]raclopride and [11C]NMSP binding potentials by P. Rosa-Neto; A.K. Olsen; S.B. Jensen; O.L. Munk; H. Watanabe; A. Gjedde; P. Cumming (S453).

P.6.063 COMT haplotypes in schizophrenia by P. Sand; P. Eichhammer; A. Putzhammer; M. Albus; D. Wildenauer; M. Borrmann-Hassenbach; S. Schwab; P. Dallinger; B. Langguth; G. Hajak (S452).

P.6.064 Evaluating venlafaxine treatment for chronic pain by M. Demitrack; N. Kunz; A.R. Entsuah (S452-S453).

P.5.046 Mirtazapine and venlafaxine administration in alcohol detoxification: Impact on anxiety and depression symptoms by E. Tzavellas; J. Liappas; C. Kontoangelos; T. Paparrigopoulos; G.N. Christodoulou (S425-S426).

P.5.045 Effects of venlafaxine on ethanol withdrawal syndrome in rats by E. Saglam; H. Kayir; T. Çelik; M. Beyazyurek; I.T. Uzbay (S425).

P.4.034 Neuropsychiatric symptoms in APOE genotyped Alzheimer's disease patients: Contributions to diagnosis and prognosis of the disease by A. Alvarez; M. Laredo; V. Couceiro; L. Fernandez-Novoa; C. Sampedro; R. Cacabelos; M. Vargas; M. Aleixandre (S399-S400).

P.4.033 Phospholipase D platelet activity in patients with dementia and acute ischaemic stroke by E. Krzystanek; G. Opala; H.I. Trzeciak; M. Krzystanek; J. Suida (S399).

P.4.035 Effects of cerebrolysin on quantitative EEG activity in elderly controls and in patients with brain damage by A. Alvarez; C. Sampedro; M. Laredo; V. Couceiro; P. Perez; R. Cacabelos; H. Moessler; E. Doppler (S400).

P.4.037 Tic reduction in Tourette's disorder with olazapine by K. Naudts; K. Dhondt; A. Sieben; F. Van den Eynde; K. Audenaert; C. Van Heeringen (S400-S401).

P.4.032 Cognitive influence of topiramate in children by F.J. Quin; G.Gutierrez del Alamo; M.J. Rebollo; P. Corredoira; R.I.Largo Gomez; E.Baca Garcia; F.J. Quintero Lumbreras (S398-S399).

P.4.026 Hippocampal galanin and acetylcholine in spatial learning of the rat by E. Elvander; T. Yoshitake; J. Kehr; J. Sandin; S.O. Ögren (S396-S397).

P.4.030 Pharmacokinetic study of memantine and donepezil in healthy young subjects by A. Periclou; D. Ventura; T. Sherman; N. Rao; H. Mengel; W. Abramowitz (S398).

P.4.046 Donepezil-treated Alzheimer's disease patients with apparent initial cognitive decline demonstrate significant benefits when therapy is continued: Results from a randomized, placebo-controlled trial by W. Kozubski; S. Hasselbalch; G. Jakab; C.J. Kalisvaart; A. Kurz; J. McCarthy; E. Triau; M. Tsolaki; L. Bergendorff; Y. Xu; N. Kumar; S. Richardson; P. Johannsen (S405).

P.4.045 Dementia patients with additional parkinsonian symptoms benefit from donepezil therapy by J. Kohler; K. Jendroska; R. Horn; M. Kamleiter; J. Möbius; M. Reipe (S404-S405).

P.4.044 Long-term efficacy of donepezil in patients with mild to moderate Alzheimer's disease: Results from a one-year placebo-controlled study and two-year follow-up study by B. Winblad; A. Wimo; A.-L. Wetterholm; A. Haglund; K. Engedal; H. Soininen; F.R.J. Verhey; G. Waldemar; R. Zhang; L. Burger; R. Schindler (S404).

P.4.040 Donepezil has significant functional and behavioral benefits in patients with severe Alzheimer's disease by H. Feldman; S. Gauthier; J. Hecker; B. Vellas; Y. Xu; J. Ieni; E. Schwam (S402).

P.4.042 Gene expression profiling of Alzheimer's lymphocytes by J. Kálmán; A. Zvara; K. Kitajka; A. Juhasz; M. Pakaski; L. Puskas; Z. Janka (S403).

P.4.043 DemTect: Final English version of a new cognitive screening test for mild cognitive impairment and early dementia by J. Kessler; E. Kalbe; P. Calabrese; B. Smith; P. Passmore; R. Bullock (S403-S404).

P.4.001 Faster forgetting of spatial memory in the PDAPP mouse-model of Alzheimer's disease by J. Sandin; G. Chen; S.J. Martin; K.S. Chen; R.G.M. Morris (S386-S387).

P.4.004 Moderately elevated plasma homocysteine and methylenetetrahydrofolate reductase genotype and risk for mild cognitive impairment and Alzheimer's disease by T. Gabryelewicz; M. Styczynska; D. Religa; B. Peplonska; A. Pfeffer; B. Wasiak; M. Barcikowska (S388).

P.4.012 Effect of memantine on levels of the amyloid beta peptide in cell cultures by D.K. Lahiri; G.M. Alley; C. Morgan; P. Banerjee; M. Farlow (S391).

P.4.013 GSK3β over-expressing mice - a mouse model for Alzheimer's disease? by P.A. Schött; A. Rask; Y. Nilsson; A. Staflund; R.V. Bhat (S391-S392).

P.4.022 Effects of subacute immobilisation stress on infarct volume after experimental stroke in rats by J.C. Leza; J.M. Caso; J.L.M. Madrigal; A. Cárdenas; J.M. Pradillo; P. Lorenzo; I. Lizasoain; J.C. Leza; M.A. Moro (S395).

P.4.023 The peroxisome proliferator-activated receptor gamma (PPARgamma) ligand rosiglitazone decreases neuroinflammatory mediators in brain after stress in rats by J.C. Leza; B. García-Bueno; J.M. Caso; J.L.M. Madrigal; C. Romera; M.A. Moro; I. Lizasoain; P. Lorenzo; J.C. Leza (S395).

P.4.050 Homocysteine induces cell death of astrocytes in vitro by M. Maler; J. Wiltfang; D. Degner; J. Kornhuber; S. Bleich (S406).

P.4.051 Cognition is physicians' main indicator of treatment efficacy in Alzheimer's disease patients by E. Triau; R. Heun; R. Holub; S. Jakobsen; I. Kloszewska; F. Tury; V. Vagenas; F.R.J. Verhey; S. Qvitzau; S. Richardson; Y. Xu; E. Schwam; R. Schindler; P. Johannsen (S407).

P.5.029 Legal complications of bipolar disorder accompanied by alcohol, cannabis, or cocaine abuse or dependence by J. Calabrese; M. Shelton; O. Elhaj; D. Rapport; K. Sak-Jackson; E. Youngstrom; K. Packer; S. Bilali; R. Findling (S419).

P.5.028 Estimates of illicit drug use during pregnancy by maternal interview and meconium analysis by C. Mortali; E. Marchei; M. Pellegrini; E. Perez-Alarcòn; C. Puig; O. Vall; R. Pacifici; L. Ordobas; S. Pachini; O. Garcia-Algar (S419).

P.5.030 Substance use disorders and their treatment response in dual diagnosis bipolar disorder by J. Calabrese; M. Shelton; O. Elhaj; D. Rapport; E. Youngstrom; K. Packer; K. Sak-Jackson; S. Bilali; R. Findling (S419-S420).

P.5.031 Tryptophan hydroxylase polymorphism, family history, and severity of illness are associated with age of alcoholism onset in a Korean population by I.W. Chung; H. Kim; W. Sribney; J.B. Hong; C.H. Lee; K.Y. Lee; H.M. Nan; Y.S. Kim; P. Manowitz (S420).

P.5.027 C-fos expression after cocaine or morphine sensitization in CB1 knockout mice by P. Murtra; M. Martin; C. Ledent; M. Patmentier; R. Maldonado (S418-S419).

P.5.024 Rates of lifetime and current cigarette and alcohol use in three different age groups in Turkey by K. Yazici; S. Tot; A. Yazici; O. Metin; N. Bal; P. Erdem (S417).

P.5.025 Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis by H. Ujike; M. Harano; T. Inada; M. Yamada; T. Komiyama; Y. Sekine; I. Sora; M. Iyo; T. Katsu; A. Nomura; K. Otani; Y. Morita; N. Ozaki; S. Kuroda (S418).

P.5.033 Apolipoprotein E epsilon 4 is associated with hippocampal volume reduction in females with alcoholism by S. Bleich; J. Wilhelm; D. Degner; W. Sperling; J. Kornhuber (S420-S421).

P.5.034 Do women have more risk of relapse than men in primary alcoholism? by D. Marra; D. Warot; I. Berlin; E. Hispard; C. Notides; C. Payan; J.F. Allilaire; J.P. Lépine; S. Dally; H.J. Aubin (S421).

P.5.041 Differential actions of nicotinic agonists on exploratory behaviour in rats by N. Moore; R. Nunan; C. Greenhalgh; G. Rees; B. Tree (S423-S424).

P.5.043 Schizotypy and memory deficits linked with ketamine dependence by K. Jansen; R. Darracott-Cankovic; C. Chandler; L. Theron (S424).

P.5.040 Thyreotropin-releasing hormone and cocaine sensitization in rats by M. Filip; K. Czepiel; E. Nowak; K. Wydra; E. Przegaliński; W. Lasoń (S423).

P.5.035 Frequency and causes of premature termination during in-patient opiate detoxification by A. Heiden; C. Baecker; R. Frey; O. Presslich; S. Kasper (S421).

P.5.036 Dependence on tramadol — a case series by A. Paiva; M. Lobo; J. Chainho (S421-S422).

P.5.037 Craving treatment: The role of citalopram and paroxetine by M. Campana; M. Riglietta; A. Crocco; M. Nava (S422).

P.5.038 Topiramate in benzodiazepine withdrawal by D.F. Zullino; A. Miozzari; R. Rajeswaran; Y. Khazaal; G. Zimmermann; S. Krenz; J. Besson (S422).

P.5.020 Patterns of drug consumption in first-episode drug-naive schizophrenic patients by L. San; B. Arranz; N. Ramirez; R. Dueñas; J.M. Sanchez; L. Miralles; M. Berrospi (S416).

P.5.003 Metoclopramide and ondansetron prn during multidrug withdrawal by A. Miozzari; R. Rajeswaran; G. Zimmermann; S. Krenz; D.F. Zullino (S409-S410).

P.5.005 Lack of relationship between DRD2 and DAT polymorphisms and dopaminergic activity assessed by the apomorphine challenge by E. Pinto; J. Reggers; M. Hansenne; W. Pitchot; S. Fuchs; P. Gorwood; D. Vaira; M. Ansseau (S410).

P.4.052 Phosphatidylserine (BCPS) did not reverse the memory impairment associated to intranigral MPTP lesion in rats by R. Andreatini; J.C. Perry; M.A.B.F. Vital; J. Anselmo-Franci; C. Da Cunha; S. Tufik; E. Miyoshi (S407).

P.4.053 Vinpocetine selectively increases vigilance in healthy young subjects by Z. Tokaji; J. Kálmán; A. Pestenácz; L. Oroszi (S408).

P.4.055 Neurological development of infants exposed to benzodiazepines in utero by N. Cerovac Cosic; M. Proçtran; N. Jovic; S. Gligorovic; S. Todorovic (S408-S409).

P.5.009 Buprenorphine: A new pharmacological option for heroin addicts' treatment by L. Guglielmino; P. Vigezzi; R. Silenzio; M. De Chiara; F. Corrado; P. Marzorati; L. Cocchi; E. Cozzolino (S411-S412).

P.5.016 Effects of nitric oxide synthase inhibitor L-NOARG on behaviour in mice after chronic ethanol inhalation by P. Pokk; K. Õkva; A. Lang; E. Sepp; M. Väli; T. Nevalainen (S414-S415).

P.5.018 Temperamental traits in multiaddictive behaviors by A. Dervaux; F.J. Bayle; M.O. Krebs; M. Lejoyeux; J. Adès (S415-S416).

P.5.019 Methylphenidate replacement: A long-term treatment of non-comorbid amphetamine abusers? by X. Laqueille; A. Dervaux; F. El Omari; M. Kanit; F.J. Baylé (S416).

P.5.015 Possible involvement of COX2 in the expression of morphine withdrawal by R. Farina; W. Milano; C. Petrella; A. Capasso (S414).

P.5.014 Diazepam in combination with piracetam in the treatment of alcohol withdrawal syndrome by V. Lazarova; M. Jakovcevska-Kujundziska; V. Filovska (S413-S414).

P.5.012 The role of muscarinic receptors in the control of acute morphine withdrawal by A. De Iovanna; W. Milano; C. Petrella; A. Capasso (S413).

P.5.013 Health, general functioning and psychopathology in patients treated with methadone and LAAM by F. Cavaglia; N. Gonçalves; G. Borges; D. Pires-Barreira; A. Matos-Pires (S413).

P.2.041 High dose glycine added to olanzapine and risperidone for the treatment of schizophrenia by M. Ermilov; D.C. Javitt; P. Lichtenberg; G. Bar; U. Heresco-Levy (S296-S297).

P.1.020 A whole gene based SNP study of the AVP 1B receptor gene: A possible protective effect in the etiology of major depression by D. Van West; J. Del Favero; Y. Aulchenko; D. Souery; J. Mendlewicz; R. Adolfsson; D. Deboutte; C. Van Duijn; C. Van Broeckhoven; S. Claes (S183).

P.1.021 The effects of venlafaxine on behavioural effects in chronically stressed rats by E. Nowakowska; K. Kus; T. Bobkiewicz-Kozłowska (S183-S184).

P.1.016 In vivo pharmacology of AZD1134, a novel 5-HT1B antagonist by T. Hudzik; J. Smolka; L. Litwin; T. Porrey; E. Pierson (S181-S182).

P.1.011 Meta-analysis of efficacy of two pilot clinical studies with a novel pentapeptide antidepressant, nemifitide, in the treatment of depression by S.A. Montgomery; J.P. Feighner; L. Sverdlov; H. Abajian; J. Hlavka; G. Nicolau; J. Freed (S179-S180).

P.1.022 Olanzapine-SSRI in the treatment of major depressive episode with somatoform symptoms by A.M. Iordache; G. Cicu; N. Marcu; M. Sobescianschi; R. Rascu (S184).

P.1.023 Antidepressants combination. How and when use them? by L.Agüera Ortiz; J.Gandara Martin; E.Rojo Rodes (S184).

P.1.033 Analysis of gepirone ER on the bech-6 and individual hamD-17 item scores by A.J. Schutte; M. Gibertini; J.H. Simmons (S188).

P.1.029 The prevalence and clinical characteristics of depression in selected school-based study in Mersin in Turkey by A.Ertekin Yazici; F. Toros; N.Gamsiz Bilgin; R. Bugdayci; T. Sasmaz; H. Camdeviren; A.Yazici Ertekin (S187).

P.1.028 Typical neuroleptics versus atypical antipsychotics in the treatment of acute mania in a natural setting by M. Letmaier; D. Schreinzer; L. Reinfried; G. Glauninger; N. Thierry; T. Kapitany; S. Kasper (S186).

P.1.025 Fluvoxamine response in nondemented elderly compared to younger depressives by D. Rossini; C. Cusin; D. De Ronchi; A. Serretti; R. Zanardi (S185).

P.1.026 Serotonin transporter promoter gene polymorphic region (5-HTTLPR) and personality in female patients with seasonal affective disorder and healthy controls by N. Thierry; M. Willeit; N. Praschak-Rieder; P. Zill; K. Hornik; A. Neumeister; E. Hilger; S. Kasper (S185-S186).

S.26.03 Schizophrenia genes identified by positional cloning affect the glutamatergic system by H. Stefansson; E. Sigurdsson; V. Steinthorsdottir; J.R. Gulcher; H. Petursson; K. Stefansson (S165-S166).

P.1.004 Repetitive transcranial magnetic stimulation (rTMS) as an add-on therapy in depression: A prospective, monocenter, randomized, double-blind, sham controlled trial by M. Walpoth; A. Hausmann; S. Mechtecheriakov; K. Kramer-Reinstadler; T. Lechner; T. Walch; E. Deisenhammer; G. Kemmler; C. Rupp; M. Kofler; H. Hinterhuber; A. Conca (S176-S177).

P.1.003 Lithium, but not valproate increases NAA concentrations in bipolar patients: An MRS study by P. Silverstone; R.H. Wu; T. O'Donnell; M. Ulrich; S.J. Asghar; C.C. Hanstock (S176).

S.28.05 Antidepressant mechanisms in anxiety disorders by D.J. Nutt; J.R. Nash; C. Bell; M. Adrover; P.A. Sargent; E.A. Rabiner; S. Hood; S. Argyropoulos; P. Grasby (S173).

P.1.034 Chronic gepirone treatment alters regional 5-HT1A receptor coupling efficiency in rat brain by N. Ward; P. Wren; B. Henry; S. McElroy; G. Walker; O. Epemolu; J. Van Kalkeren; D.R. Hill (S188-S189).

P.1.035 Onset of improvement in emotional and painful physical symptoms of depression with duloxetine treatment by M. Wohlreich; S. Brannan; C. Mallinckrodt; M. Detke; Y. Lu; J. Watkin; G. Tollefson (S189).

P.1.067 Bipolar disorder: One year follow-up study by M. Can Saka; S. Ozer; A. Ulusahin (S203).

P.1.066 The effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients by A.S. Gonul; F. Akdeniz; F. Taneli; O. Donat; C. Eker; S. Vahip (S203).

P.1.061 Characteristics of attenders and non-attenders at a bipolar disorder psycho-education programme by C. Even; H. Richard; M. Kalck-Stern; S. Friedman; J.D. Guelfi (S200-S201).

P.1.062 Naturalistic study of outcome of mood stabilizing treatment in bipolar disorder by J.S. Garnham; A. Munro; A. Teehan; C. Slaney; A. Duffy; M. MacDougall; M. Passmore; M. Alda (S201).

P.1.064 Differential response to imipramine in mice lacking D2 or D4 dopamine receptor gene by M.O. Rojas-Corrales; E. Berrocoso; A.B. Martin; D. Grandy; J.A. Micó; R. Moratalla (S202).

P.1.073 R-citalopram functionally antagonizes escitalopram in vivo and in vitro: Evidence for kinetic interaction at the serotonin transporter by S. Stórustovuí; C. Sánchez; P. Pörzgen; L.T. Brennum; A.K. Larsen; M. Pulis; B. Ebert (S205-S206).

P.1.081 Chronic treatment of various antidepressants increases Golf proteins in the rat nucleus accumbens and striatum by H. Taoka; T. Hamamura; S. Endo; M. Miki; Y. Lee; S. Miyata; T. Ishihara; T. Habara; T. Oka; K. Toma (S209).

P.1.079 Temporal profile of symptom improvement in antidepressant treatment by R. Hirschfeld; T. Burt; E. Batzar; H. Sackeim (S208).

P.1.077 Long-term use of olanzapine/fluoxetine combination for major depressive disorder: A 76-week study by S. Corya; S. Andersen; H. Detke; L. Van Campen; T. Sanger; D. Williamson; S. Dube (S207).

P.1.078 Long-term use of olanzapine or olanzapine/fluoxetine for bipolar depression by E. Vieta; M. Tohen; T. Ketter; J. Calabrese; S. Andersen; H. Detke; R. Risser; S. Corya (S207-S208).

P.1.059 EPID — the first epidemiological study on depression in Slovakia pharmacotherapy in depressive patients by V. Novotný; J. Pečeňák; A. Heretik; A. Heretik; A. Ritomský (S199-S200).

P.1.043 Lithium induced alterations in NTP levels in human brain: A proton decoupled 31P MRS study by A. Yildiz; G.S. Sachs; Z. Tunca; C.M. Demopulos; C.M. Moore; P.F. Renshaw (S192-S193).

P.1.044 Amisulpride in combination with maprotiline in the treatment of psychotic depression — a clinical experience by M. Jakovcevska-Kujundziska; V. Filovska; L. Lazarova; R. Krsteska (S193).

P.1.045 Interactions between dopaminergic system and HPT axis in depression: Implication for pathogenesis of suicidal behavior by F. Duval; M.C. Mokrani; J. Monreal; B. Hamel; S. Fattah; J.P. Macher (S193-S194).

P.1.046 Comparison of the safety of two approaches to amitriptyline dose individualization by G. Mihajlovic; D. Milovanovic; D.Ignjatovic Ristic; S. Jankovic; M. Rikanovic (S194).

P.1.041 Growth hormone response to L-DOPA and dexamethasone suppression tests before and after treatment in depressive patients by E. Esel; S. Kartalci; M. Kula; M.T. Turan; Y. Hacimusalar; A. Tutus; S. Sofuoglu (S191-S192).

P.1.037 Quality of life post MI: Influence of depression and effect of treatment with sertraline by J.R. Swenson; A.H. Glassman; K. Swedberg; D. Barton; L. Van Zyl; L. Forman; C. O'Connor (S190).

P.1.038 Treatment of bulimia nervosa with sertraline: A randomized controlled trial by C. Sabatino; W. Milano; C. Petrella; L. Milano; A. Capasso (S190).

P.1.039 Depression in the elderly: A comparative and correlational study by A. Matos-Pires; L. Fernandes; D. Pires-Barreira; G. Borges; F. Cavaglia (S190-S191).

P.1.047 Effects of antidepressant treatment on alpha 2-adrenoreceptor function in depressed patients by F. Duval; M.C. Mokrani; J. Monreal; P. Bailey; B. Hamel; J.P. Macher (S194).

P.1.048 Metabolism phenotype and in vitro drug-drug interaction studies with nemifitide, a novel pentapeptide antidepressant by G. Nicolau; J.P. Feighner; P. Silber; G. Chen; H. Abajian; M. Bathala (S194-S195).

P.1.055 Regional cerebral blood flow changes with simple photon emission tomography and tis neuropsychological correlations in bipolar disorders by A. Benabarre; A. Martínez-Arán; F. Colom; D. Muñoz; J.M. Goikolea; B. Corbella; C. Torrent; M. Comes; J. Sánchez-Moreno; F. Lomeña; E. Vieta (S198).

P.1.056 Canadian network for bipolar disorder (CAN-BD): Preliminary report of data on the first 126 patients by L.N. Yatham; P. Silverstone; C. Gorman; P. Baruch; J. Leblanc; P. Cervantes; S. Beaulieu (S198-S199).

P.1.057 Contrasting effects of reboxetine and fluoxetine on regional expression of Fos-like immunoreactivity in the rat forebrain by S. Miyata; T. Hamamura; Y. Lee; M. Miki; T. Habara; T. Oka; S. Endo; H. Taoka; S. Kuroda (S199).

P.1.053 Depressive symptoms and cognitive decline in elderly people by I.-K. Jung; J.W. Yang; Y.J. Seo (S197).

P.1.049 The 5-HTTLPR polymorphism in the SCL6A4 gene is associated with antidepressant induced mania in bipolar disorder by E. Masoliver; A. Menoyo; V. Pérez; E. Grasa; M. Baiget; D. Puigdemont; E. Alvarez (S195).

S.08.01 The metabotropic glutamate receptor progress towards novel therapeutics by D.D. Schoepp; C. Swanson; A. Linden; L. Levine; W. Potter (S113).

S.08.04 Allosteric modulators of mGluR by F. Gasparini (S114-S115).

S.09.01 Immunization therapy for Alzheimer's disease by C. Hock; R.M. Nitsch (S115-S116).

S.07.04 Towards pharmacogenomics: A large-scale association study on response to haloperidol by D. Rujescu; I. Giegling; M. Schafer; N. Dahmen; T. Sander; A. Szegedi; M.R. Toliat; H.-J. Möller; B. Bondy; A.M. Hartmann; H.H. Stassen (S112).

S.06.04 Can we measure 5-HT release with PET? by P.M. Grasby; E. Hirani; S. Hume; P. Cowen; E. Rabiner; T. Sharp (S110).

S.09.03 Statins in the treatment of Alzheimer's disease by K. Beyreuther; T. Hartmann (S116).

S.11.02 The amygdala and social cognition by A. Aleman (S123-S124).

S.11.03 Fear, amygdala and the X chromosome by J. Morris; D.H. Skuse; R.J. Dolan (S124-S125).

S.11.04 The amygdala and mood disorders by M. Phillips; N. Lawrence; S. Surguladze; N. Kerr; A. Williams (S125-S126).

S.11.01 The amygdala and dopamine by A. Grace; A. Rosenkranz (S122-S123).

S.10.05 Role of 5HT in eating disorders by W. Kaye; G. Frank; N. Barbarich; S. Henry; U. Bailer (S121-S122).

S.10.01 Animal models for eating disorders by R.A.H. Adan; J. Hillebrand; A. Van Elburg; M. Koeners; H. Van Engeland; M.J.H. Kas (S119-S120).

S.10.02 Psychoneuroendocrinological aspects of anorexia nervosa by H. Van Engeland; A. Van Elburg; M. Kas; R.A.H. Adan (S120-S121).

S.10.04 The brain and eating disorders by J. Treasure; R. Uher; I. Campbell (S121).

S.05.05 Chronobiological treatment of bipolar depression by F. Benedetti; C. Colombo; A. Pontiggia; A. Bernasconi; B. Barbini; E. Smeraldi (S108-S109).

S.02.05 The pathophysiology of pain in depression by J.A. Micó; M.O. Rojas-Corrales; E. Berrocoso; J. Elorza (S98-S99).

S.02.04 The impact of depression on the outcome of physical diseases by J.-C. Bisserbe; M. Flament; S. Paterniti (S97-S98).

S.03.01 In vivo and in vitro models of AD demonstrate a role of distinct phosphorylation sites of tau in neurofibrillary tangle formation by F. Chen; A. Schild; P. Kurosinski; L. Pennanen; F. Hoerndli; D. David; A. Ferrari; R.M. Nitsch; J. Götz (S99-S100).

S.03.03 Characterization and reconstitution of gamma-secretase by H. Steiner; D. Edbauer; K. Shirotani; C. Haass (S101).

S.01.02 Efficacy of partial dopamine agonists by H.-J. Möller (S95-S96).

S.01.03 Therapeutic implications of the NMDA receptor antagonist model psychosis by J. Krystal; D.H. D'Souza; D.H. Mathalon; A. Belger; E. Perry (S96).

S.04.1 Analysis of cerebrospinal fluid of depressed patients by M. Rosenhagen; D. Milfay; G. Maccarrone; M. Uhr; F. Holsboer; C. Turck (S102).

S.04.08 Expression of endothelin-converting enzyme-1 in human cerebral cortex protects against Alzheimer's disease by B. Funalot; T. Ouimet; A. Claperon; C. Fallet; A. Delacourte; J. Epelbaum; T. Subkowski; J.P. David; P. Amouyel; J.-C. Schwartz; N. Helbecque (S105).

S.05.02 Anticonvulsant prophylaxis in bipolar disorder: Is phenytoin the prototype? by R.H. Belmaker; A. Mishory; Y. Bersudsky (S106-S107).

S.05.04 Inhibition of myo-inositol-phosphate synthase by valproate; a mechanism for mood stabilization? by M.L. Greenberg; D. Ding; G. Shaltiel; S. Ju; G. Agam; R.H. Belmaker (S107-S108).

S.04.07 Role of monoamine oxidase in imidazoline2 binding site mediated function in rat brain by L. Paterson; R.J. Tyacke; E.S.J. Robinson; D.J. Nutt; A.L. Hudson (S104-S105).

S.04.02 Biochemical modulation of AMPA receptor function by antidepressants by P. Svenningsson; E. Tzavara; G. Nomikos; B. McEwen; P. Greengard (S102-S103).

S.20.03 Neuroendocrinological modulation of reward systems and vulnerability by M. Le Moal; M. Marinelli; V. Deroche-Gamonet; P.V. Piazza (S150).

S.20.01 Adrenal & CSF neurosteroids as mediators of HPA axis upregulation and symptom production in premenopausal women with PTSD by A. Rasmusson; A. Guidotti; D. Charney; D. Vojvoda; D. Lipschitz; D. Weisman; J. Krystal (S151-S152).

S.21.03 Developing an animal model for post-traumatic stress disorder by G. Yadid; I. Gispan-Herman; Y. Kesner; Y. Weizman; A. Mendelman; J. Zohar (S152-S153).

S.20.02 Effects of psychostimulants in the absence of dopamine transporter by B. Giros; E. Morice; M. Nosten-Bertrand (S149-S150).

S.19.02 IGF-1 signaling: Role in neuroprotection and major depression by I. Torres-Aleman; J.L. Trejo; E. Garcia-Galloway; E. Carro (S146-S147).

S.21.05 Ten myths of PTSD by J. Zohar (S153-S154).

S.23.05 Modeling schizophrenia in animals by B. Lipska (S158-S159).

S.23.04 From the animal models to the clinical treatment modalities in schizophrenia by J. Horacek; V. Bubenikova; M. Kopecek; M. Brunovsky; T. Palenicek; C. Höschl (S158).

S.22.04 Neurobiology of treatment response in affective disorders by M. Alda; P. Grof; G.A. Rouleau; G. Turecki; L.T. Young (S155).

S.22.05 The neurobiology of pleiotropic traits in schizophrenia by P.S. Holzman; S. Matthysse; D.L. Levy (S155-S156).

S.14.04 Progression in braim abnormalities and illness severity in schizophrenia by D.H. Mathalon; E.V. Sullivan; K.O. Lim; A. Pfefferbaum (S133-S134).

S.14.02 Progression prior to illness by E. Johnstone; S. Lawrie; D. Job (S133).

S.14.05 Long-term efficacy and safety of atypical and conventional antipsychotic drugs in first episode schizophrenia by T. Sharma; J.A. Lieberman; J.P. McEvoy; D.O. Perkins; R.M. Hamer; R.B. Zipursky; R.S. Kahn; R.E. Gur; F. Centorrino; I. Glick; A.I. Green; C.B. Nemeroff; A.J. Rothschild; S.M. Strakowski; M. Tohen; G.D. Tollefson (S134-S135).

S.15.02 Cortical and limbic interactions in memory processes by J. Aggleton; T. Jenkins; E. Amin; S. Vann (S135).

S.15.03 Serotoninergic receptor subtypes in cognition by M.C. Buhot; M. Wolff; L. Segu (S135-S136).

S.12.03 Physiological regulation of α7 nicotinic receptor activity by endogenous levels of the brain metabolite kynurenic acid: Clinical implications by R. Schwarcz; E.F.R. Pereira; M. Alkondon; L.E.F. Almeida; W.P. Fawcett; W.R. Randall; P. Guidetti; M.T. Sapko; P. Yu; D.A. Tagle; E.X. Albuquerque (S128).

S.13.01 CRF1 antagonists for anxiety by E. Zorrilla; E. Fekete; B.J. Mason; P. Wirsching; K.D. Janda; G.F. Koob (S130-S131).

S.15.05 Hippocampal neuropeptides in learning and memory: Implications for cognitive dysfunction and aging by S.O. Ögren; A. Kuzmin; J. Kehr; L. Terenius; J. Sandin (S137-S138).

S.18.01 Schizophrenia: Effects of aging on cognition by K. Davis; D. Stewart; J. Friedman; M. Buchsbaum; P. Harvey; P. Hof; J. Buxbaum; V. Haroutunian (S145).

S.16.03 Histaminergic neurons, attention and learning by P. Blandina; M.B. Passani (S140-S141).

S.16.04 Histamine H3-receptor ligands: Effects of inverse agonists and protean ligands by J.M. Arrang; S. Morisset; A. Rouleau; F. Gbahou; X. Ligneau; J. Tardivel-Lacombe; H. Stark; W. Schunack; C.R. Ganellin; J.-C. Schwartz (S141).

P.1.085 The effect of bupropion on the activity of dopamine transporter in depression — preliminary results by Z. Szabo; M. Argyelan; B. Kanyo; A. Juhasz; Z.S. Kovacs; L. Pavics; Z. Janka (S210).

P.1.218 Previous episode burden and response to lithium and lamotrigine in bipolar I disorder by M. Frye; E. Vieta; T. Ketter; J.F. Goldberg; Z. Antonijevic; J. Calabrese (S267).

P.1.217 Predictors of response to lithium and lamotrigine prophylaxis in bipolar I disorder by T. Ketter; C. Bowden; E. Vieta; J.F. Goldberg; Z. Antonijevic; R. Leadbetter (S267).

P.1.219 Role of estrogens in antidepressive effects of venlafaxine by K. Kus; E. Nowakowska; A. Lewandowska (S267).

P.1.221 Actions of the selective melanin concentrating hormone1 receptor antagonist, (+)SNAP-7941, in models of potential antidepressant and anxiolytic activity in rodents by M.J. Millan; A. Dekeyne; A. Gobert; B. Di Cara; V. Audinot; D. Cussac; J.-C. Ortuno; J.-L. Fauchère; J.-A. Boutin; M.J. Brocco (S268).

P.1.216 Lamotrigine but not lithium prevents or delays depressive episodes in bipolar I disorder by L. Yatham; G. Goodwin; C. Bowden; J. Calabrese; R. White; R. Leadbetter (S266-S267).

P.1.211 Burden of manic vs depressive symptoms in subjects with bipolar disorder by R. Hirschfeld; J. Calabrese; M. Frye; M. Reed; K. Wagner (S264-S265).

P.1.212 Effects of lithium and lamotrigine on body weight after 18 months in bipolar I disorder by J. Calabrese; A.H. Young; C. Bowden; Z. Antonijevic; G. Evoniuk (S265).

P.1.213 Safety and tolerability of lamotrigine in bipolar I disorder by E. Vieta; A. Young; M. Berk; G. Asnis; J. Calabrese; G. Sachs; C. Bowden (S265).

P.1.214 Lamotrigine controls bipolar depression without destabilising mood: An analysis of data from 8 placebo-controlled trials by H. Grunze; J. Calabrese; L. Yatham; T. Suppes; S. McElroy; J.F. Goldberg; C. Bowden (S265-S266).

P.1.222 NK1 receptors in human blood lymphocytes and granulocytes by S. Baroni; I. Masala; L. Giusti; L. Betti; G. Giannaccini; D. Marazziti (S269).

P.1.223 In vitro neuro-immunomodulator induced postreceptor changes in immune system and brain by F. Kovářů; H. Kovářů; A. Fišerová; V. Lisá; P. Zelníčková (S269).

P.1.231 The brain-derived neurotrophic factor (BDNF) in bipolar affective disorder: A case-control association study by P. Oswald; D. Souery; J. Del-Favero; C. Van Broeckhoven; J. Mendlewicz (S273).

P.1.232 Menopausal depression: Comparing HRT and HRT plus fluoxetine by P. Liu; Q. Yu; W.P. Bai; F.F. He; W. Shi; Y.Y. Wu; D.J. He; J.H. Xiao; Y. Zheng; Q.P. Liao (S273-S274).

P.1.233 Effects of paroxetine and venlafaxine-XP on heart rate variability in depression by L. Watkins; J.R.T. Davidson; K.M. Connor; K.L. Beebe; S. Krulewicz; K. Abraham; W. Zhang; M. Owens; C.B. Nemeroff (S274).

P.1.228 Old vs. new antidepressants following ECT by G. Papadimitriou; I.M. Zervas; M.I. Andreadaki; K. Psarros; K. Kontoangelos; C. Dimitrakopoulos; N. Vaidakis; Y. Papakostas (S272).

P.1.226 Release of serotonin and serotonin receptors in the effects of antidepressants by K. Pruus; R. Rudissaar; A. Vaarmann; L. Allikmets (S271).

P.1.227 Anxiety in depression and antidepressants by L. Allikmets; A. Vaarmann; V. Matto (S271).

P.1.210 Concomitant use of lamotrigine and valproate in bipolar I disorder by C. Bowden; J. Calabrese; G. Sachs; G. Evoniuk (S264).

P.1.193 Thyroid auto-antibodies in bipolar affective disorder: Is there a link with lithium treatment? by E. Palazidou; S. Bhandari; D. Samellas; M. Lai; M. Botazzo (S257).

P.1.196 Effects of bupropion SR on body weight and depressive symptoms in obese patients treated for 50 weeks by E. Goodale; P. Bradley; B. Haight; V. Foster; N. Richard; J. Modell (S258).

P.1.190 Prevalence and management of depression with painful physical symptoms in a Canadian claims database by J. Hopkins; A.W. Gilsenan; P. Corey-Lisle; C.J. Longo; J. Raskin (S255-S256).

P.1.186 Assessment of sexual dysfunction in depressive patients treated with sertraline by C. Tudor; G. Grigorescu; R. Ciurea; M.D. Gheorghe (S253-S254).

P.1.189 Venlafaxine and SSRIs: Pooled remission analysis by C.B. Nemeroff; A.R. Entsuah; L. Willard; M. Demitrack; M. Thase (S255).

P.1.198 Follow-up of patients with major depression treated with intravenous mirtazapine by A. Konstantinidis; J. Ptak-Butta; J. Stastny; D. Winkler; E. Pjrek; C. Barnas; A. Neumeister; S. Kasper (S259).

P.1.208 The direct health care cost of depressive disorders in the United States in 2000 by P.E. Greenberg; R. Kessler; H.G. Birnbaum; E. Moyneur; S.A. Leong; S.W. Low; P.A. Berglund; P.K. Corey-Lisle (S263).

P.1.204 Duloxetine vs placebo in the prevention of relapse of major depressive disorder by M. Detke; I. Gilaberte; D. Perahia; F. Wang; R. McNamara; P. Tran; C. Miner; S.A. Montgomery (S261-S262).

P.1.203 Cost-effectiveness of atypical antipsychotics for treatment of acute mania in the UK by L. McGarry; A.P. Bird; D. Thompson; J. Cookson; S.C. Martin; M.C. Weinstein (S261).

P.1.199 Remission rates following therapy with bupropion or selective serotonin reuptake inhibitors by M.E. Thase; Y. Wang; N. Richard; M. Mitton; B. Haight; E. Goodale (S259).

P.1.200 Red blood cell triiodothyronine uptake as membrane parameter of depression by L. Stárková; Z. Fisar; I. Paclt; J. Vevera (S259-S260).

P.2.025 Growth and sexual maturation during treatment with risperidone by F. Dunbar; V. Kusumakar; D. Daneman; M. Schulz (S289).

P.2.028 Preliminary evidence of striatal D2 receptor density as a possible biological marker of prognosis in naive schizophrenic patients by I. Corripio Collado; V. Pérez Solá; M. Ferrer Vinardell; M. Serra Buil; M.J. EscartíXátiva; E. Alvarez Martínez (S290-S291).

P.2.023 Prolactin levels in children after long-term treatment with risperidone by R. Findling; V. Kusumakar; D. Daneman; T. Moshang; G. De Smedt; C. Binder (S288).

P.2.022 Open label study for the effect of amantadine on weight gain induced by olanzapine; an interim analysis by W.M. Bahk; K.U. Lee; J.H. Chae; C.U. Pae; T.Y. Jun; K.S. Kim (S288).

P.2.018 Risperidone in the treatment of acute schizophrenia by T. Raedler; A. Schreiner; D. Naber; K. Wiedemann (S286).

P.2.020 Comparison of efficacy and tolerability of quetiapine and haloperidol in acute exacerbation of chronic or subchronic schizophrenia by B. Taneli; K. Alptekin; M. Bilici; S. Birsoz; E. Eker; B. Cosar; E. Goka; E. Goktepe; H. Guz; O. Karamustafalioglu; S. Kultur; B.A. Levent; E. Onder; T. Oral; A. Özsahin; B. Veznedaroglu; S. Yuksel; N. Yurtseven (S287).

P.2.029 Suicide attempts in schizophrenia: The role of impulsivity and substance abuse by A. Dervaux; F.J. Baylé; X. Laqueille; M.C. Bourdel; J.P. Olié; M.O. Krebs (S291).

P.2.038 Initial stages of insulin resistance in young antipsychotic-free and not in antipsychotic-naive schizophrenic patients by B. Arranz; R. Dueñas; N. Ramirez; P. Fernandez; S. Sarró; L. San (S295-S296).

P.2.040 Size matters: The impact of the volume of the amygdala on its activation during the processing of facial expressions of fear by P. Shaw; K. Kucharska-Pietura; T. Russell; F. Zelaya; E. Amaro; M.L. Phillips; A.S. David (S296).

P.2.035 Risperidone versus zuclopentixol in acute psychosis in emergency psychiatry: A prospective naturalistic study by J.E.J.M. Hovens; S. Beijeman; J. Tollenaar; P.J.T. Dries; A.J.M. Loonen (S294).

P.2.032 Latency period of risperidone, a study with 123I-IBZM spect by S. Oller; I. Corripio Collado; R. Perez-Egea; V. Pérez Solá; A. Catafau; E. Alvarez (S292-S293).

P.2.033 Quality of life of patients with schizophrenia measured by schizophrenia quality of life scale by A. Suwalska; A. Rajewski; F. Rybakowski; D. Lojko; A. Permoda; J.K. Rybakowski (S293).

P.2.034 A novel fast-disintegrating oral formulation of the atypical antipsychotic resperidone by J. Mintzer; P.H. Lechat; B. Remmerie; E. Mannaert (S293).

P.2.016 Speech perception ability of schizophrenia by S.H. Lee; S.J. Lee; Y.C. Chung (S286).

P.2.015 Atypical antipsychotics: Glutamate, amino acids and monoaminergic parameters by F.M.M.A. Van der Heijden; S. Tuinier; D. Fekkes; A.E.S. Sijben; R.S. Kahn; W.M.A. Verhoeven (S285-S286).

P.1.242 Gender differences in depressive symptoms among college students in Bombay by R.M. Parikh; S.B. Sonawalla; N. Chakraborthy; G. Mehra; S. Dracass; M. Fava (S277-S278).

P.1.241 Symptom questionnaire assessment of depressive symptoms among college students by S.B. Sonawalla; Y. Mahal; E. Masson; A. Yeung; T. Petersen; D. Mischoulon; M. Fava (S277).

P.1.240 Proton magnetic resonance spectroscopy in depression: Elevated creatine and unaffected myo-inositol levels in the frontal brain by R. Frey; S. Gruber; L. Reinfried; A. Stadlbauer; V. Mlnarik; S. Kasper; E. Moser (S277).

P.1.238 Maprotiline in the treatment of depression by S. Pejkovska-Dimovska; M.Kaeva Pejkovska; M.Mrga Dimovska; D. Mircevska; V. Videnova (S276).

P.2.011 One year outcome on symptoms, motor side effects and cognition in first episode psychosis: A comparison of two novel antipsychotics by A. Malla; R. Norman; D. Scholten; L. Townsend; R. Manchanda; J. Takhar; R. Haricharan (S284).

P.2.010 Differential involvement of the frontal lobe in patients with schizophrenia and schizotypal disorder by M. Suzuki; S.-Y. Zhou; Y. Kawasaki; H. Hagino; T. Takahashi; S. Nohara; M. Matsui; H. Seto; M. Kurachi (S283-S284).

P.1.185 Does pretreatment anxiety or insomnia predict acute response to bupropion SR? by A.J. Rush; R. Schmid; B. Haight; S. Zisook; C. Rockett; T. Carmody (S253).

P.1.184 Tolerability of mirtazapine versus SSRIs in patients with major depression by E. Den Braber; A.J. Schutte; S. Van der Flier (S253).

P.1.119 Genetic dissection of psychopathological symptoms: Insomnia in mood disorders and CLOCK gene polymorphism by F. Benedetti; A. Serretti; L. Mandelli; C. Lorenzi; A. Pirovano; C. Colombo; E. Smeraldi (S225).

P.1.118 Changes in depressive neuropsychological functioning during antidepressant treatment by M. Florita; F. Benedetti; C. Colombo; A. Bernasconi; A. Pontiggia; M. Cigala Fulgosi; B. Barbini; E. Smeraldi (S224-S225).

P.1.120 Glycogen synthase kinase 3-b influences age at onset of bipolar disorder by F. Benedetti; A. Bernasconi; C. Lorenzi; A. Pontiggia; C. Colombo; E. Smeraldi (S225).

P.1.121 Rapid assessment of cognitive distorsions in major depression by M. Cigala Fulgosi; F. Benedetti; M. Florita; C. Colombo; B. Barbini; E. Smeraldi (S225-S226).

P.1.117 Morning light therapy as an augmenting strategy of antidepressant treatment by A. Bernasconi; F. Benedetti; C. Colombo; A. Pontiggia; M. Florita; E. Smeraldi (S224).

P.1.116 Phase-response effects of lormetazepam in depressive insomnia by A. Pontiggia; F. Benedetti; E. Smeraldi; A. Bernasconi; M. Florita; C. Colombo; I. Cropanese (S223-S224).

P.1.112 Serum lipids, depression and anhedonia in suicide attempters by K.G. Paplos; V.P. Kontaxakis; B.J. Havaki-Kontaxaki; A.G. Alaveras; M.R. Issidorides; G.N. Christodoulou (S222).

P.1.114 Effects of sertraline and venlafaxine on serum TNF-α in major depressive disorder by C. Tuglu; H. Kara; O. Caliyurt; E. Vardar; E. Abay (S222-S223).

P.1.115 CLOCK gene and circadian mood fluctuations in bipolar depression by F. Benedetti; A. Serretti; C. Colombo; B. Barbini; C. Lorenzi; E. Campori; E. Smeraldi (S223).

P.1.123 CLOCK gene influences insomnia during antidepressant treatment by F. Benedetti; A. Serretti; C. Cusin; L. Mandelli; A. Pirovano; R. Zanardi; C. Colombo; E. Smeraldi (S226).

P.1.124 Milnacipran in the treatment of adolescent depression or dysthymia by S. Tauscher-Wisniewski; M.H. Friedrich (S226-S227).

P.1.133 The use of antidepressants in bipolar depression: A retrospective and naturalistic study by J.M. Montes; A. Asiel; C. Lahera; P. Sopelana; J. Saiz-Ruiz (S230-S231).

P.1.130 The compounds Org 34517 and Org 34850 are potent antagonists of the glucocorticoid receptor both in vitro and in vivo by F. Thomson; M.W. Craighead; L. Watson; Z. Turnbull; L. McIntosh; M. Speake; A. Hillier; S. Eason; M. Shahid; H.M. Marston; D.R. Hill (S229).

P.1.125 A 20-month, double-blind, maintenance study of lithium versus divalproex monotherapy in bipolar I and II disorder accompanied by rapid cycling by J. Calabrese; M. Shelton; D. Rapport; E. Youngstrom; E. Shirley; O. Elhaj; K. Packer; S. Bilali; R. Findling (S227).

P.1.126 Effects of lamotrigine on neurocognitive measures in bipolar I patients by L.N. Yatham; K.H. Davis; A. Khan; L.D. Ginsberg; G.M. Asnis; F.K. Goodwin (S227-S228).

P.1.128 Dysphoric mania: A controlled study of the benefits of olanzapine combined with valproate or lithium by M. Tohen; R. Baker; E. Brown; L. Schuh; P. Trzepachz; S. Dando (S228).

P.1.111 A steady-state evaluation of the effect of rifampicin on the pharmacokinetics of gepirone ER and metabolites by Y.W.F. Lam; L. Ereshefsky; A. Port; C.J. Timmer; P. Dogterom (S221-S222).

P.1.092 Olanzapine versus lithium in relapse prevention in bipolar disorder: A randomized double-blind controlled 12-month clinical trial by A. Evans; M. Tohen; A. Marneros; C. Bowden; W. Greil; A. Koukopoulis; R.H. Belmaker; T. Jacobs; R. Baker; D. Williamson; M. Dossenbach; G.B. Cassano (S213).

P.1.091 Olanzapine's efficacy for relapse prevention in bipolar disorder: A randomized double-blind placebo-controlled 12-month clinical trial by M. Tohen; C. Bowden; J. Calabrese; J. Chou; T. Jacobs; R. Baker; D. Williamson; A. Evans (S212-S213).

P.1.089 Analysis of treatment-emergent mania with olanzapine/fluoxetine combination by P. Keck; S. Corya; S. Briggs; M. Case; M. Tohen (S212).

P.1.090 Olanzapine/fluoxetine combination improves long-term quality of life in bipolar depression by M. Tohen; L. Shi; C. Vallarino; V. Prabhakar; R. Juarez; M. Namjoshi (S212).

P.1.106 The efficacy and side effect profile of the antidepressants by M. Keresztes-Nagy; I. Kecskés; Z. Rihmer (S219).

P.1.107 Depression and painful physical symptoms in Europe by R. Peveler; A. Garcia-Cebrian; A. Lothgren; P. Ghandi (S219-S220).

P.1.100 “Useful” side effect: Result of the good selection by I. Kecskés; M. Keresztes-Nagy; Z. Rihmer (S216).

P.1.103 Membrane lipids and serotonin uptake after long-term administration of antidepressants by Z. Fisar; M. Anders; E. Tvrzická; K. Fuksová (S217-S218).

P.1.169 Bipolar and pregnant? No problem! A clinical evaluation of lithium use during pregnancy by A. Kramer; E.A.M. Knoppert-Van der Klein; I.L. Van Kamp; F.J. Walter; I.M. Van Vliet; F.G. Zitman (S246).

P.1.171 Impairment in major depressive disorder by W. Pitchot; K. Demyttenaere; A. Albert; L. Zhang; P. De Cock (S247).

P.1.172 Bright light therapy in seasonal affective disorder — does it suffice? by E. Pjrek; D. Winkler; A. Konstantinidis; N. Thierry; A. Heiden; S. Kasper (S247-S248).

P.1.173 Diagnosis of depression by the primary care physician and the patient by K. Demyttenaere; W. Pitchot; A. Albert; L. Zhang; P. De Cock (S248).

P.1.180 Paroxetine improves sleep disturbances associated with major depression by J.R.T. Davidson; J. Christie; D. Duff; E. Dubé (S251).

P.1.174 Assessment of cerebral regions associated with sexual arousal in depressive women by using functional magnetic resonance imaging by J.-C. Yang; M.S. Lee; J.S. Yoon; H.K. Kang; G.W. Jeong; H.J. Kim; S.J. Eun; T.J. Zheng (S248-S249).

P.1.175 The effects of lithium treatment on bone mineral density of bipolar patients by Y. Eren; M. Yyldyz; Y. Çivi; D. Gündodar; R. Özcankaya (S249).

P.1.176 The effect of depression on life quality of patients with type II diabetes mellitus by Y. Eren; Ö. Erdi; Ö. Erdi; R. Özcankaya; D. Gündodar (S249).

P.1.177 Olanzapine/fluoxetine combination in the treatment of rapid-cycling bipolar depression by S. Corya; P. Keck; J. Calabrese; S. Andersen; M. Gillig; R. Baker; M. Tohen (S250).

P.1.159 A multi-dimensional approach to major depression by G. Tacchini; S. Fumagalli; O. Fusi; A.C. Altamura (S241-S242).

P.1.144 Amitriptiline mechanism of action may relate to oleate activated phospholipase D inhibition by M. Krzystanek; I. Krupka-Matuszczyk; H.I. Trzeciak; E. Krzystanek (S235).

P.1.145 Efficacy and safety of mirtazapine in elderly depressed patients by B.K. Yeon; B.H. Oh; M.S. Lee; C.W. Lee; B.S. Gee; S.G. Ryu (S235-S236).

P.1.142 Obsessive-compulsive symptoms in mania by M. Raja; A. Azzoni (S234).

P.1.137 Autoimmune thyroiditis (AIT) and affective disorders — a prospective pilot study by D. Degner; S. Bleich; M. Haust; I. Zerr; E. Rüther; J. Meller (S232).

P.1.138 Eye movement disturbances in patients with bipolar illness by A. Kepa; A. Borkowska; J. Hauser; A. Leszczynska; M. Kosmowska; J.K. Rybakowski (S232-S233).

P.1.147 Phenotype dynamics and its clinical correlates in patients treated by paroxetine by A. Zourkova; E. Hadasova; L. Pilarova; O. Kuliskova; M. Robes (S237).

P.1.148 The novel antidepressant agomelatine (S 20098) acts independently of 5-HT1A receptors in the rat by L. Lanfumey; N. Hanoun; P.A. Boyer; E. Mocaër; M. Hamon (S237).

P.1.157 Effect of the CYP3A4 inhibitor ketoconazol on the pharmacokinetics of mirtazapine in healthy volunteers by P. Baumann; M.W. Van den Heuvel; J.M.A. Sitsen; C.B. Eap; P.A.M. Peeters (S241).

P.1.149 Escitalopram for treatment of depression and anxiety disorder in adult outpatients by N. Klein; G. Wiesegger; D. Winkler; T. Attarbaschi; N. Mossaheb; S. Kasper; J. Tauscher (S237-S238).

P.1.150 Side effects causing dropout in outpatients treated with antidepressants by Ö. Uzun; A. Cansever; A. Özsahin; A. Ateh; U. Çalyhkan (S238).

P.1.152 An appropriate strategy for screening antidepressant drugs using the mouse forced swimming test and the tail suspension test by F. Chenu; B.A. Nic Dhonnchadha; N. Ripoll; D.J.P. David; M. Hascoët; M. Bourin (S239).